Contrasting Myokardia (MYOK) & PTC Therapeutics (PTCT)

Myokardia (NASDAQ: MYOK) and PTC Therapeutics (NASDAQ:PTCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Valuation and Earnings

This table compares Myokardia and PTC Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myokardia $39.20 million 48.23 -$13.15 million ($0.76) -69.60
PTC Therapeutics $82.71 million 11.68 -$142.11 million ($2.89) -8.06

Myokardia has higher earnings, but lower revenue than PTC Therapeutics. Myokardia is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

63.6% of Myokardia shares are owned by institutional investors. Comparatively, 86.1% of PTC Therapeutics shares are owned by institutional investors. 33.4% of Myokardia shares are owned by insiders. Comparatively, 8.1% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Myokardia has a beta of 4.21, suggesting that its stock price is 321% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.


This table compares Myokardia and PTC Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myokardia -53.49% -14.92% -11.53%
PTC Therapeutics -75.64% -75.19% -31.76%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Myokardia and PTC Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myokardia 0 0 6 0 3.00
PTC Therapeutics 1 5 2 0 2.13

Myokardia presently has a consensus target price of $54.83, suggesting a potential upside of 3.65%. PTC Therapeutics has a consensus target price of $19.17, suggesting a potential downside of 17.70%. Given Myokardia’s stronger consensus rating and higher probable upside, research analysts plainly believe Myokardia is more favorable than PTC Therapeutics.


Myokardia beats PTC Therapeutics on 11 of the 14 factors compared between the two stocks.

Myokardia Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with's FREE daily email newsletter.

Leave a Reply